Antibody Drug Conjugate (ADC)
Chair: Michail Ignatiadis

What is an ADC (Antibody Drug Conjugate)? 

ADC  are a type of anti-cancer drug that combine two products:

  • An antibody that identifies a specific molecule on the surface of cancer cells
  • A potent chemotherapy drug linked to the antibody that is thereby delivered
    specifically to the cancer cells identified by the antibody.

Discover the Task Force: Interview with Michail Ignatiadis

The primary objective of the ADCs Task Force is the development of clinical and translational projects related to the efficacy and/or toxicity of this new class of drugs called Antibody-Drug Conjugates (ADC) in several tumour types involving different disease-oriented groups.

The task force brings together a multidisciplinary group of experts, comprising clinicians dedicated to different cancer types like, for example, breast, lung, genito-urinary and gastrointestinal cancer, but also researchers involved in translational research and health-related quality of life.

Important challenges and knowledge gaps in the field of ADCs were identified
and are being targeted by the Task Force:

  • Mechanisms of resistance to ADCs and therapeutical implications;
  • Optimal sequencing of ADCs with other treatment modalities;
  • New ADCs indications, e.g. in rare cancers;
  • Mechanisms of Interstitial lung disease (ILD) related to ADCs and early detection and prevention.